Some historical perspective
Following the completion of the Human Genome Project (www.ornl.gov/sci/techresources/Human_Genome/home.shtm), three key advances are creating unprecedented opportunities for understanding the pathogenic basis of common human diseases: 21 (i) extensive catalogues of DNA sequence variants across the human genome are being compiled; (ii) dramatic progress is occurring in molecular genetic technologies for evaluating the polymorphic sites in human samples with increasing efficiency and decreasing cost; and (iii) large-scale, population-based human samples are becoming increasingly available, for example, the European Prospective Investigation into Cancer and Nutrition (EPIC), 22 the Busselton Health Study, 23 and many others. The construction of large, national cohorts such as the Medical Research Council/Wellcome Trust UK Biobank (www.ukbiobank.ac.uk/) is occurring in many nations, with planned or ongoing initiatives for national cohorts in a number of countries in Western Europe, Scandinavia, North America, and Australasia. The focus of much of this activity has been on common complex human conditions such as obesity and cancer that are determined by multiple genetic and environmental factors; such diseases constitute the principal health burden in the developed nations. 1, 4, 5, 24 Despite this manifest progress, in many ways we are right at the beginning of our ability to map complex disease genes. The completion of the sequencing of the human genome was the key enabling event in this enterprise. However, the main focus of the Human Genome Project was on the 'consensus' human sequence, which by definition does not contain information about individual differences of medical relevance. 25 To make use of the consensus sequence, the SNP Consortium (TSC) was formed in 1999, alongside many other public and private projects, with the aim of discovering common polymorphism sites in the human genome. 26 The increasingly complete catalogue of common genetic variants that is being widely applied to association studies of complex phenotypes is a direct extension of this early project. The natural follow-on from the single nucleotide polymorphism (SNP) discovery phase was to genotype discovered SNPs in multiple individuals to begin to assess their potential utility for disease mapping. This latter enterprise is ongoing in the International HapMap Project (www.hapmap.org/). The next logical stage in the progression from human consensus sequence to SNP identification to SNP genotyping will involve applications to gene discovery, clinical medicine, and epidemiology, reflecting the culmination of the initial human genomic framework studies.
The completion of hundreds of family-based genome-wide scans for linkage to complex disease genes, coupled with the availability of high-density SNP maps across the genome and decreasing genotyping costs, is beginning to shift emphasis away from linkage analysis and microsatellite markers towards SNP genotyping and different analytical strategies based on allelic association. [27] [28] [29] [30] [31] A small but growing number of genes associated with complex diseases have been discovered using association-based genetic mapping. 32, 33 Epidemiology and genetics: a growing union resources for the joint investigation of environmental and genetic hypotheses is a key advance for the growing integration of epidemiology with genetics. These resources are inherently epidemiological in nature as they aim to promote understanding of disease aetiology at a population level. A better understanding of how aetiological factors act at a population level will be a critical step for the clinical utilization of new genomic knowledge and tools to improve health outcomes. 4, 34, 35 Ultimately, genetic knowledge will become useful in the clinical arena only if it is placed back into an epidemiological and medical/public health context. [5] [6] [7] 9, 36 It is therefore clear that very large, well-characterized population-based studies drawn from multiple ethnic groups will play a central role in the future implementation of SNP-based gene discovery and in diagnostic tests for complex phenotypes in the outbred, highly admixed populations that increasingly characterize modern human societies. 37 Another important way in which genetics is being actively enriched by mainstream epidemiology is in the area of study design. Recently, more and more articles have begun to address the features of a 'good' genetic association study. 8, 33, [37] [38] [39] The increasing focus on study design has resulted from the realization that genetic association studies of complex phenotypes have either tended to fail to discover susceptibility loci or failed to replicate those studies that did. 8, 37, [40] [41] [42] [43] [44] Despite the widespread use of genetic case/control studies, this lack of consistency is a generally recognized limitation. 43, 44 The lack of reproducibility is often ascribed to small samples with inadequate statistical power, biological and phenotypic complexity, population-specific linkage disequilibrium, effect-size bias, and population stratification. 27, 43, 45, 46 Additional potential reasons for the nonreplication of true positive association results include inter-investigator and interpopulation heterogeneity in study design, analytic method, phenotype definition, genetic structure, environmental exposures, and markers genotyped. It is now routinely argued that large sample sizes (generally, thousands rather than hundreds), rigorous P-value thresholds, and replication in multiple independent datasets are necessary for reliable results. 4, 33, 39, 42, 43 A new epidemiology?
The last decade has been a tumultuous and exciting time in human genetics. Explosive growth in technical capabilities and genomic knowledge has been tempered by initial failures to find genes for complex phenotypes using any strategy-linkage or association. Our statistical capabilities and ability to process and interpret data still lag far behind our technical capability to produce very large amounts of genomic data. What have we learnt over the last decade of gene discovery attempts in complex human disease? One important lesson learnt is that everything in human genetics is context specific-specific to the population, environmental exposures, genomic region, and gene under investigation. There is no one paradigm for gene discovery, study design, or analytic approach that will be optimal in all situations. Thus, some complex phenotypes may be modulated by many rare alleles; some may be modulated by a smaller number of common alleles. Despite the large number of reviews and 'guru' statements on optimal study design and analytic strategies, it has become increasingly clear that flexible, mixed approaches and hypothesis-free study designs are desirable. A feature associated with the genomics revolution has been an unfortunate tendency towards hyperbole in the promise of human gene discovery. This has led to unrealistic expectations regarding the scope of the deliverables and the timeline for the integration of disease-gene discovery into clinical medicine and epidemiology, and exaggerated cynicism and pessimism within the academic community. For researchers interested in investigating the pathogenesis of complex human diseases, one of the most important tasks in the coming years is not to add to the hyperbole surrounding genetic epidemiology, but carefully to establish and communicate a realistic set of expectations.
Where do we stand at present with regard to gene discovery by linkage disequilibrium (LD) mapping? For most complex human diseases, the reality of multiple diseasepredisposing genes of modest individual effect, gene-gene interactions, gene-environment interactions, interpopulation heterogeneity of both genetic and environmental determinants of disease, and the concomitant low statistical power have made it clear that both initial detection and replication will probably be very difficult. 8, 44, 47 However, in addition to an improved understanding of the complexity of the task at hand, we have some important new tools and knowledge that offer considerable prospects for the future success of gene discovery efforts. The technology for detecting SNPs has undergone rapid development, and increasingly complete catalogues of SNPs across the human genome have been constructed. A large number of groups are currently active in addressing methodological problems in LD mapping and haplotypic approaches. Our growing understanding of the architecture of the human genome and the extent of human genetic variability-aided by projects such as HapMap-will probably accelerate our ability to use the tools at hand to map genes for many common conditions. We stand at the threshold of the availability of numerous very large cohort opportunities throughout the world. All these recent developments, taken together with a small but growing number of successful gene localization studies for complex phenotypes, suggest that we should be cautiously optimistic about our potential to disover the genes underlying common human diseases.
An important recent trend that also gives rise to considerable hope has been the assimilation of genetic epidemiology into mainstream epidemiology and public health in many academic institutions. The growing engagement of epidemiologists in genetic research should ameliorate some of the problems with discovery and nonreplication that have plagued complex disease genetics-many of which can be blamed on poor epidemiological study design and overinterpretation of marginal results. At the same time, observational epidemiology has begun to benefit from new genetic approaches to causal inference regarding exposures and disease. One such approach is 'Mendelian randomization', 48 which is based on the plausible proposition that the association between a disease and a genetic polymorphism that mimics the biological link between a proposed exposure and disease is not generally susceptible to the reverse causation or confounding that can distort interpretations of conventional observational studies. The escalating utilization of genetic data in epidemiological investigations in novel and creative ways represents fresh hope for a discipline beleaguered by the potential for reverse causality and many forms of confounding. Both genetics and epidemiology have had real difficulties with the investigation of complex human disease aetiology apropos defining 'true' risk factors, replicating results among different studies, and providing useful information for the appropriate targeting of preventive or therapeutic measures. Each discipline has much to learn from the other and there is much to be gained from active collaboration. Our understanding of complex disease pathophysiology has already begun to enter into the realm of clinical genetics, 49 and we have every reason to anticipate that the impact of genomics on clinical practice and on our understanding of biology and epidemiology will continue to accelerate. This issue of the International Journal of Epidemiology with the special theme 'Genetic Epidemiology' is both a testament to this fact and a promise for the future of both epidemiology and genetics.
